Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer
Purpose In the present study, we addressed the inconsistency between the testing criteria and diverse phenotypes for germline TP53 mutation in patients with breast cancer in the Chinese population. Method We proposed a new added item (synchronous or metachronous bilateral breast cancer) as one of th...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2024-08, Vol.206 (3), p.653-666 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
In the present study, we addressed the inconsistency between the testing criteria and diverse phenotypes for germline
TP53
mutation in patients with breast cancer in the Chinese population.
Method
We proposed a new added item (synchronous or metachronous bilateral breast cancer) as one of the testing criteria (aimed at high-penetrance breast cancer susceptibility genes) and applied it for determining
TP53
germline mutation status in 420 female patients with breast cancer using multigene panel-based next-generation sequencing, Sanger sequencing, and mass spectrometry.
Results
We found that 1.4% of patients carried a pathogenic or likely pathogenic germline
TP53
mutation. Compared with
BRCA
mutation carriers (8.0%) and non-carriers (7.1%),
TP53
mutation carriers (33.3%) developed breast cancer earlier. The majority of
TP53
mutation carriers (66.7%) developed breast cancer after age 30 and had bilateral breast cancer (33.3%). Pedigree investigation of four
TP53
carriers and a patient with a
TP53
variant of unknown significance revealed that neither of their parents harbored the same mutations as the probands, indicating that the mutations might occur de novo.
Conclusion
Our study revealed distinguishing features of
TP53
carriers among Chinese women with breast cancer, which is inconsistent with the currently used testing criteria; therefore, the newly proposed testing criteria may be more appropriate. |
---|---|
ISSN: | 0167-6806 1573-7217 1573-7217 |
DOI: | 10.1007/s10549-024-07341-7 |